3,4-二氢-2H-苯并[E][1,2,4]噻二嗪-3-羧酸1,1-二氧化物 | 154106-40-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻二嗪
• 中文名称: 3,4-二氢-2H-苯并[E][1,2,4]噻二嗪-3-羧酸1,1-二氧化物
• 英文名称: 1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-3-carboxylic acid
• 英文别名: 1,1-dioxo-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-3-carboxylic acid
• CAS: 154106-40-8
• 化学式: C₈H₈N₂O₄S
• mdl: MFCD00924809
• 分子量: 228.23
• InChiKey: KHMJUYHKYXZJFI-UHFFFAOYSA-N

物化性质

• 沸点：
  525.1±60.0 °C(Predicted)
• 密度：
  1.550±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
  申请人：Mayer C. Scott

  公开号：US20050176652A1

  公开（公告）日：2005-08-11

  This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure wherein R 1 , R 2 , R 3 , R 4 , and R 5 are each, independently, hydrogen, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R 8 ; R 6 and R 7 are each, independently, —OH, —OR 9 , O-tert-butyldimethylsilyl, O-trialkylsilyl of 1-6 carbon atoms per alkyl moiety, O-triphenylsilyl, R 8 , R 10 , R 11 , and R 12 are each, independently, hydrogen, —CN, —NO 2 , halogen, CF 3 , alkyl of 1-6 carbon atoms, acetyl, benzoyl, or alkoxy of 1-6 carbon atoms; R 9 is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R 8 ; Y is O, S, NH, NMe, or CH 2 ; W is halogen, —CN, CF 3 , alkyl of 1-6 carbon atoms, haloalkyl of 1-6 carbon atoms, nitroalkyl of 1-6 carbon atoms, cyanoalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-12 carbon atoms, alkoxy of 1-6 carbon atoms, or phenyl mono-, di-, or tri-substituted with R 8 ; Z is —NO 2 , —NH 2 , —NHR 13 , or —NHCO-Het; R 13 is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, benzoyl in which the phenyl moiety is substituted with R 8 , or R 13 is an α-amino acid in which the a carboxyl group forms an amide with the nitrogen of Z, wherein if said amino acid is glutamic acid or aspartic acid, the non-α carboxylic acid is an alkyl ester in which the alkyl moiety contains from 1-6 carbon atoms; Het is pyridyl substituted with R 8 , thienyl substituted with R 8 , furyl substituted with R 8 , oxazolyl substituted with R 8 , pyrazinyl substituted with R 8 , pyrimidinyl substituted with R 8 , or thiazolyl substituted with R 8 ; R 14 is R 8 , —NH 2 , —CO 2 H, or —NH-acyl of 2-7 carbon atoms; n=0-3; with the proviso that when Z is —NHR 13 and Y is O, at least one of R 1 , R 2 , R 3 , R 4 , and R 5 is hydrogen, or at least one of R 6 and R 7 is OH, or a pharmaceutically acceptable salt thereof.

  本发明提供具有结构式I的平滑肌细胞增殖抑制剂，其中R1、R2、R3、R4和R5各自独立地为氢、2-7个碳原子的酰基、2-7个碳原子的卤代酰基、2-7个碳原子的硝基酰基、2-7个碳原子的氰基酰基、3-8个碳原子的三氟甲基酰基或苯甲酰基，其中苯基部分被R8取代；R6和R7各自独立地为-OH、-OR9、O-叔丁基二甲基硅烷基、1-6个碳原子的三烷基硅基或三苯基硅基；R8、R10、R11和R12各自独立地为氢、-CN、-NO2、卤素、CF3、1-6个碳原子的烷基、乙酰基、苯甲酰基或1-6个碳原子的烷氧基；R9为2-7个碳原子的酰基、2-7个碳原子的卤代酰基、2-7个碳原子的硝基酰基、2-7个碳原子的氰基酰基、3-8个碳原子的三氟甲基酰基或苯甲酰基，其中苯基部分被R8取代；Y为O、S、NH、NMe或CH2；W为卤素、-CN、 、1-6个碳原子的烷基、1-6个碳原子的卤代烷基、1-6个碳原子的硝基烷基、1-6个碳原子的氰基烷基、2-12个碳原子的烷氧基、1-6个碳原子的烷氧基或苯基单、二或三取代的R8；Z为- 、-NH2、-NHR13或-NHCO-Het；R13为2-7个碳原子的酰基、2-7个碳原子的卤代酰基、2-7个碳原子的硝基酰基、2-7个碳原子的氰基酰基、3-8个碳原子的三氟甲基酰基、苯甲酰基，其中苯基部分被R8取代，或者R13是α-氨基酸，其中α-羧基与Z的氮形成酰胺，如果该氨基酸是谷氨酸或天冬氨酸，则非α-羧酸是含有1-6个碳原子的烷基酯；Het是被R8取代的吡啶基、噻吩基、呋喃基、噁唑基、吡嗪基、嘧啶基或噻唑基；R14为R8、-NH2、-CO2H或2-7个碳原子的-NH-酰基；n=0-3；条件是，当Z为-NHR13且Y为O时，R1、R2、R3、R4和R5中至少有一个为氢，或R6和R7中至少有一个为-OH，或其药学上可接受的盐。
• Treatment of demyelinating disorders
  申请人：——

  公开号：US20040204347A1

  公开（公告）日：2004-10-14

  This invention is directed to pharmaceutical compositions and methods for treating demyelinating disorders based upon inhibitors of the interaction of glutamate with the AMPA and of the interaction of glutamate with the kainate receptor complex.

  本发明涉及治疗脱髓鞘疾病的药物组合物和方法，其基础是抑制谷氨酸与 AMPA 的相互作用以及谷氨酸与 kainate 受体复合物的相互作用的抑制剂。
• DERIVES D'ACIDE 3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE 1,1-DIOXYDE-3-CARBOXYLIQUE, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT
  申请人：RHONE-POULENC RORER S.A.

  公开号：EP0636124A1

  公开（公告）日：1995-02-01
• PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS
  申请人：Eisai Co., Ltd.

  公开号：EP1100504A2

  公开（公告）日：2001-05-23
• [EN] 3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE-3-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME<br/>[FR] DERIVES D'ACIDE 3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE 1,1-DIOXYDE-3-CARBOXYLIQUE, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT
  申请人：RHONE-POULENC RORER S.A.

  公开号：WO1993021170A1

  公开（公告）日：1993-10-28

  (EN) Compounds of formula (I), wherein R is (a) a hydrogen atom, (b) an alkyl radical, (c) an allyl radical, (d) a phenyl radical, (e) a 2-or-3-pyridyl alkyl radical, (f) a 2-quinolylalkyl radical, (g) a naphthylalkyl radical, (h) a cycloalkylalkyl radical, (i) a 2H-3-naphtho[1,8-cd]isothiazol-2-yl-1,1-dioxide)alkyl radical, (j) a (5,6-dihydro 1H,4H-1,2,5-thiadiazolo[4,3,2-ij]quinolyl-2,2-dioxide)alkyl, (k) an -alk-CO-R5 radical, (l) an -alk-R6-R7 radical, (m) a 4-phenylpirerazinyl-alkyl radical wherein the phenyl nucleus is optionally substituted by one or more substituents selected from halogen atoms and alkyl or alkoxy radicals, (n) a 10-phenothiazinylalkyl radical (o) a (10-alkyl-2-phenothiazinyl)alkyl radical, (p) a 3-indolylalkyl radical, (q) a phenylalkyloxy radical, (r) a 1-phenylalkyl-4-piperidyl radical, (s) a 2-thienylalkyl radical, or (t) a phenylalkyl radical wherein the phenyl is unsubstituted or substituted by one or more substituents selected from halogen atoms and alkyl, alkoxy, polyfluoroalkyl, amino, nitro, cyano, phenyl, vinyl, polyfluoroalkoxy, alkoxycarbonyl, carboxy, phenylalkyloxy, phenylalkyl, benzoylamino, phenylcarbonyl and phenoxy radicals in which the phenyl nucleus is optionally substituted by one or more substituents selected from halogen atoms and alkyl, alkoxy or polyfluoroalkyl radicals; R1 is a carboxy, alkoxycarbonyl, tetrazolyl, -CO-NH2, -CO-NH-alk, -CO-N(alk)2, -CO-NHOH, -CO-N(alk)OH, -CO-NH-O-R8, -CO-N(alk)-OR8 or a group which is convertible in vivo into a carboxy radical; each of R2, R3 and R4, which are the same or different, is a hydrogen or halogen atom or an alkyl or alkoxy radical; R5 is a hydroxy, alkoxy, phenyl or -NR9R10 radical; R6 is an oxygen, sulphur or nitrogen atom or a SO, SO2 or -N-alk radical, R7 is an alkyl, phenylalkyl or phenyl radical optionally substituted by one or more hydrogen atoms; R8 is an alkyl or phenylalkyl radical; each of R9 and R10, which are the same or different, is a hydrogen atom or an alkyl or phenyl radical; and alk is an alkyl or alkylene radical, salts thereof; preparation thereof; and drugs containing same.(FR) La présente invention concerne des composés de formule (I), dans laquelle R représente (a) un atome d'hydrogène, (b) un radical alkyle, (c) un radical alkyle, (d) un radical phényle, (e) un radical 2 ou 3-pyridylalkyle, (f) un radical 2-quinolylalkyle, (g) un radical naphtylalkyle, (h) un radical cycloalkylalkyle, (i) un radical 2H-3-naphto[1,8-cd]isothiazol-2-yl-1,1-dioxyde)alkyle, (j) un radical (5,6-dihydro 1H,4H-1,2,5-thiadiazolo[4,3,2-ij]quinolyl-2,2-dioxyde)alkyle, (k) un radical -alk-CO-R5, (l) un radical -alk-R6-R7, (m) un radical 4-phénylpipérazinylalkyle dont le noyau phényle est éventuellement substitué par un ou plusieurs substituants choisis parmi les atomes d'halogène et les radicaux alkyle ou alcoxy, (n) un radical 10-phénothiazinylalkyle, (o) un radical (10-alkyl-2-phénothiazinyl)alkyle, (p) un radical 3-indolyalkyle, (q) un radical phénylalkyloxy, (r) un radical 1-phénylalkyl-4-pipéridyle, (s) un radical 2-thiénylalkyle ou (t) un radical phénylalkyle dans lequel le phényle est non substitué ou substitué par un ou plusieurs substituants choisis parmi les atomes d'halogène et les radicaux alkyle, alcoxy, polyfluoroalkyle, amino, nitro, cyano, phényle, vinyle, polyfluoroalcoxy, alcoxycarbonyle, carboxy, phénylalkyloxy, phénylalkyle, benzoylamino, phénylcarbonyle et phénoxy dont le noyau phényle est éventuellement substitué par un ou plusieurs substituants choisis parmi les atomes d'halogène et les radicaux alkyle, alcoxy ou polyfluoroalkyle, R1 représente un radical carboxy, alcoxycarbonyle, tétrazolyle, -CO-NH2, -CO-NH-alk, -CO-N(alk)2, -CO-NHOH, -CO-N(alk)OH, -CO-NH-O-R8, -CO-N(alk)-OR8 ou un groupe convertible en radical carboxy in vivo, R2, R3 et R4, identiques ou différents, représentent chacun un atome d'hydrogène ou d'halogène ou un radical alkyle ou alcoxy, R5 représente un radical hydroxy, alcoxy, phényle, ou -NR9R10, R6 représente un atome d'oxygène, de soufre ou d'azote ou un radical SO, SO2 ou -N-alk, R7 représente un radical alkyle, phénylalkyle ou phényle éventuellement substitué par un ou plusieurs atomes d'halogène, R8 représente un radical alkyle ou phénylalkyle, R9 et R10, identiques ou différents, représentent un atome d'hydrogène ou un radical alkyle ou phényle et alk représente un radical alkyle ou alkylène, leurs sels, leur préparation et les médicaments les contenant.